Patents by Inventor Kathleen M. Rupprecht

Kathleen M. Rupprecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrooxy cycloalkane derivatives
    Patent number: 8530521
    Abstract: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: September 10, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Robert K. Baker, Kathleen M. Rupprecht, Michael Man-Chu Lo, Brent Whitehead
  • Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
    Patent number: 8153626
    Abstract: Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: April 10, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert K. Baker, Linda L. Chang, Marc Chioda, Harry R. Chobanian, Ying-Duo Gao, Yan Guo, Linus S. Lin, Ping Liu, Ravi P. Nargund, Kathleen M. Rupprecht, Shouwu Miao
  • Cicletanine derivatives
    Patent number: 8119806
    Abstract: A compound having the structure wherein X is selected from the group consisting of: a bond, —NHCH2(CH2)nCH2OC(O)—, —CH2NHC(O)CH2NHC(O)—, —CH2OC(O)—, —OCH(CH3)OC(O)—, —OCH2OC(O)—, —O—, —NR1—, —CR1R3—, —(CH2)p—, —(CH2)qNR1C(O)—, —CHR5NR2C(O)—, —(CH2)qC(O)—, —(CH2)qC(O)NR1—, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: February 21, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Iyassu K. Sebhat, Christopher L. Franklin, Kathleen M. Rupprecht, Robert K. Baker, Ravi P. Nargund, Lin Yan, Pei Huo, Dong-Ming Shen, Nicoletta Almirante, Stefano Biondi, Massimiliano Ferrario, Alessia Nicotra
  • NITROOXY CYCLOALKANE DERIVATIVES
    Publication number: 20110230532
    Abstract: A compound having the structure wherein Y is selected from the group consisting of —C(O)OR2, —C(O)NHR8, —C(CH2)1-2OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Application
    Filed: July 27, 2009
    Publication date: September 22, 2011
    Inventors: Amjad Ali, Robert K. Baker, Kathleen M. Rupprecht, Michael Man-Chu Lo, Brent Whitehead
  • Heterocycle-substituted 3-alkyl azetidine derivatives
    Patent number: 7906652
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: March 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert K. Baker, Jeffrey J. Hale, Shouwu Miao, Kathleen M. Rupprecht
  • Substituted 3-alkyl and 3-alkenyl azetidine derivatives
    Patent number: 7906503
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: March 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert K. Baker, Jianming Bao, Shouwu Miao, Kathleen M. Rupprecht
  • SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS
    Publication number: 20100317645
    Abstract: Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
    Type: Application
    Filed: December 7, 2007
    Publication date: December 16, 2010
    Inventors: Robert K. Baker, Linda L. Chang, Marc Chioda, Harry R. Chobanian, Ying-Duo Gao, Yan Guo, Linus S. Lin, Ping Liu, Ravi P. Nargund, Kathleen M. Rupprecht, Shouwu Miao
  • DIURETICS
    Publication number: 20100029678
    Abstract: A compound having the structure wherein X is selected from the group consisting of: a bond, —NHCH2(CH2)nCH2OC(O)—, —CH2NHC(O)CH2NHC(O)—, —CH2OC(O)—, —OCH(CH3)OC(O)—, —OCH2OC(O)—, —O—, —NR1—, —CR1R3—, —(CH2)p—, —(CH2)qNR1C(O)—, —CHR5NR2C(O)—, —(CH2)qC(O)—, —(CH2)qC(O)—, —(CH2)qC(O)NR1—, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating, hypertension.
    Type: Application
    Filed: July 27, 2009
    Publication date: February 4, 2010
    Inventors: Amjad ALI, Iyassu K. Sebhat, Cristopher L. Franklin, Kathleen M. Rupprecht, Robert K. Baker, Ravi P. Nargund, Lin Yan, Pei Huo, Dong-Ming Shen, Nicoletta Almirante, Stefano Biondi, Massimiliano Ferrario, Alessia Nicotra
  • Substituted 3-alkyl and 3-alkenyl azetidine derivatives
    Publication number: 20090069284
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Application
    Filed: October 21, 2008
    Publication date: March 12, 2009
    Inventors: Robert K. Baker, Jianming Bao, Shouwu Miao, Kathleen M. Rupprecht
  • Substituted 3-alkyl and 3-alkenyl azetidine derivatives
    Patent number: 7485732
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: February 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Shouwu Miao, Kathleen M. Rupprecht
  • (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
    Patent number: 6809199
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 26, 2004
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Carbocyclic potassium channel inhibitors
    Patent number: 6632836
    Abstract: The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski, Frank Kayser, Andrew Kotliar, Chou Juitsai Liu, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht, William A. Schmalhofer, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
    Publication number: 20030092712
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: May 15, 2003
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
    Patent number: 6455548
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: September 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer Chee, Jill N. Johanson, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht
  • 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
    Publication number: 20020013348
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: 1
    Type: Application
    Filed: February 27, 2001
    Publication date: January 31, 2002
    Inventors: Jennifer Chee, Jill N. Johanson, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht
  • Heterocyclic potassium channel inhibitors
    Patent number: 6303637
    Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Benzamide potassium channel inhibitors
    Patent number: 6194458
    Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Tetracyclic triterpene derivatives with immunosuppressant activity
    Patent number: 6100293
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: August 8, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht
  • Furanyl, tetracyclic triterpene derivatives with immunosuppressant activity
    Patent number: 6083980
    Abstract: The compounds of Formula I ##STR1## are useful as immunosuppressive agents.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: July 4, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht
  • Immunosuppressant tricyclic compounds
    Patent number: 6051590
    Abstract: The compounds of Formula I are useful as immunosuppressive agents.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Frank Kayser, Robert K. Baker, Shouwu Miao, William H. Parsons, Kathleen M. Rupprecht